戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 otential role for bilirubin as an endogenous immunomodulatory agent.
2 ndirect antioxidant, as well as an important immunomodulatory agent.
3 y cytokines and for the use of heparin as an immunomodulatory agent.
4  inform the application of minocycline as an immunomodulatory agent.
5  that has also been used to test a number of immunomodulatory agents.
6 infection to combined antiviral and specific immunomodulatory agents.
7 sible adverse effects of this combination of immunomodulatory agents.
8  outcomes in the era of myeloma-targeted and immunomodulatory agents.
9 timicrobial drugs, anticancer therapies, and immunomodulatory agents.
10 ic antibodies, antibody-drug conjugates, and immunomodulatory agents.
11   Mesenchymal stromal cells offer promise as immunomodulatory agents.
12 oids, with increasing use of rituximab other immunomodulatory agents.
13 s were treated ex vivo with chemotherapy and immunomodulatory agents.
14  improved loading, targeting, and release of immunomodulatory agents.
15 internalization, making them effective TLR-9 immunomodulatory agents.
16 antibacterial, antimalarial, anticancer, and immunomodulatory agents.
17  application of these compounds as potential immunomodulatory agents.
18 ted in combination therapy trials with other immunomodulatory agents.
19 when combined with proteasome inhibitors and immunomodulatory agents.
20 active tumors) are more likely to respond to immunomodulatory agents.
21 inical trials have reinvigorated interest in immunomodulatory agents.
22 , a risk that is increased by treatment with immunomodulatory agents.
23  are in development as antiproliferatives or immunomodulatory agents.
24 nsights for the use of cysteine proteases as immunomodulatory agents.
25      These compounds may represent promising immunomodulatory agents.
26 ystem agents, herbal/dietary supplements and immunomodulatory agents.
27 by which IMiDs drugs function as therapeutic immunomodulatory agents.
28 ing agents, have recently been identified as immunomodulatory agents.
29 d two to four previous regimens-including an immunomodulatory agent, a proteasome inhibitor, and dara
30 ults indicate that anti-CD45 mAbs are potent immunomodulatory agents, able to sustain indefinite isle
31 D) have focused largely on the use of single immunomodulatory agents administered within 100 days of
32  antibodies) and therapeutic (antivirals and immunomodulatory agents) agents.
33 omise (chemotherapy, solid-organ transplant, immunomodulatory agents, AIDS) with bacterial infection,
34 t, the addition of checkpoint inhibitors and immunomodulatory agents alleviated NK cell exhaustion.
35                         However, these broad immunomodulatory agents, already limited by their side e
36                                        Newer immunomodulatory agents also are being explored in pedia
37 se treatments, including corticosteroids and immunomodulatory agents, although often effective, can h
38  an injectable proteasome inhibitor, an oral immunomodulatory agent and dexamethasone followed by tre
39        Despite the continuing development of immunomodulatory agents and supportive care, the prognos
40  on how to best implement existing and novel immunomodulatory agents and taper salvage agents are oft
41 ies, such as advanced drug-delivery systems, immunomodulatory agents and targeted therapies, offer th
42 ts recent clinical trials of TLR agonists as immunomodulatory agents and their therapeutic potential
43 study provides a framework to identify novel immunomodulatory agents and to prioritize compounds for
44 cancer vaccines, adoptive T-cell therapy and immunomodulatory agents and will summarize the immune ef
45 four previous lines of therapy (including an immunomodulatory agent), and had an Eastern Cooperative
46 four previous lines of therapy (including an immunomodulatory agent), and had an Eastern Cooperative
47 egimens including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody were e
48 ry to at least one proteasome inhibitor, one immunomodulatory agent, and daratumumab (triple-class re
49 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease pr
50 properties of the biomaterial, the delivered immunomodulatory agent, and the target cell populations
51 ity to inhibitors of Bruton tyrosine kinase, immunomodulatory agents, and immunotherapy.
52 and second-generation proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies.
53 that tested the efficacy of a combination of immunomodulatory agents, anti-thymocyte globulin and peg
54 b, mammalian target of rapamycin inhibitors, immunomodulatory agents, antibodies and cyclin pathway-d
55 or COVID-19 include supportive intervention, immunomodulatory agents, antiviral therapy, and plasma t
56 er acetate (GA), a parenterally administered immunomodulatory agent approved for MS treatment, we tes
57 sis is 0.05% cyclosporine A and is the first immunomodulatory agent approved for treatment of dry eye
58              Data for efficacy of other oral immunomodulatory agents are based primarily on case repo
59        Animal models, commonly used to study immunomodulatory agents, are limited by species-specific
60                      Cytokines, as essential immunomodulatory agents, are secreted by various cellula
61  and steroids as inductive agents and use of immunomodulatory agents as maintenance therapies.
62                                              Immunomodulatory agents attempt to increase the efficacy
63 se and a significant PFS benefit compared to immunomodulatory-agent-based triplet therapy.
64 unicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibo
65           Thus, IFN-lambda acted as a unique immunomodulatory agent by modifying transcriptional and
66 ay of treatment, other immunosuppressive and immunomodulatory agents can be used in the multi-modalit
67                                          New immunomodulatory agents currently being tested in contro
68 VHD are reviewed with particular emphasis on immunomodulatory agents currently incorporated into clin
69              The efficacy of the anti-cancer immunomodulatory agent cyclophosphamide (CTX) relies on
70  warrants further examination as a potential immunomodulatory agent for human disease.
71 nale for the use of 2ME2 as a tolerable oral immunomodulatory agent for the treatment of autoimmune d
72                    Lenalidomide is an active immunomodulatory agent for the treatment of myelodysplas
73  Glatiramer acetate (GA) has been used as an immunomodulatory agent for the treatment of relapsing-re
74 xt, it may also have potential utility as an immunomodulatory agent for transplantation.
75 iNKT cells) are being developed as potential immunomodulatory agents for a variety of applications.
76 hropoiesis-stimulating agents, androgens, or immunomodulatory agents for anemia, cytoreductive drugs
77 idney transplants, and individuals receiving immunomodulatory agents for autoimmune and inflammatory
78 t that n-3 PUFAs may be clinically useful as immunomodulatory agents for demyelinating diseases throu
79 servoir systems, and scaffolds encapsulating immunomodulatory agents for local administration.
80  adenoviruses expressing cytokines as potent immunomodulatory agents for the generation of protective
81 d adalimumab can be considered as first-line immunomodulatory agents for the treatment of ocular mani
82 b can be considered as potential second-line immunomodulatory agents for the treatment of severe ocul
83  adalimumab can be considered as second-line immunomodulatory agents for the treatment of uveitis ass
84     An azido group was incorporated into the immunomodulatory agent FTY720, accomplishing the first s
85 g the Toll-like receptor (TLR) pathway using immunomodulatory agent GIT27.
86 eutic response using the currently available immunomodulatory agents has not yet been achieved.
87                             Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL.
88 st decade, a number of immunosuppressive and immunomodulatory agents have been approved for the treat
89 ravenous immunoglobulin, steroids, and other immunomodulatory agents have been used frequently.
90                                              Immunomodulatory agents have significant potential to en
91                                              Immunomodulatory agents (IA) are commonly used to treat
92 oteasome inhibitor (ie, bortezomib), an oral immunomodulatory agent (ie, lenalidomide), and dexametha
93  and subsequently engineered them to release immunomodulatory agents IFN-beta and granulocyte-macroph
94 nriched at different stages of resistance to immunomodulatory agent (IMiD)-based therapy.
95                                              Immunomodulatory agents (IMiDs) are a cornerstone of tre
96                                              Immunomodulatory agents (IMiDs) target not only MM cells
97 yeloma (MM), including alkylators, steroids, immunomodulatory agents (IMiDs), proteasome inhibitors (
98 itin ligase complex, and a binding target of immunomodulatory agents (IMiDs).
99 mary immunodeficiency diseases as well as an immunomodulatory agent in a variety of autoimmune and in
100 oactive properties, is well recognized as an immunomodulatory agent in allergic and inflammatory reac
101              Bortezomib is a promising novel immunomodulatory agent in allogeneic transplantation.
102 system and is regarded as a highly promising immunomodulatory agent in cancer therapy.
103 lpha treatment may potentially be used as an immunomodulatory agent in HIV-1 cure strategies.IMPORTAN
104 xime (MBO), an antiparasitic compound, as an immunomodulatory agent in PDAC.
105 as been used as a preventive and therapeutic immunomodulatory agent in several animal species.
106 e a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly sel
107 hance antitumor immune responses using novel immunomodulatory agents in combination with standard of
108 rapeutic combinations based on endocrine and immunomodulatory agents in HR(+) breast cancer.
109 ct a fundamental role for these receptors as immunomodulatory agents in normal and subverted B lineag
110  suitable for translational studies of novel immunomodulatory agents in psychotic disorders.
111                                     Standard immunomodulatory agents including steroids, intravenous
112 rativa, or atopic dermatitis) who started an immunomodulatory agent, including methotrexate, tumor ne
113 l utility to enrich for clinical response to immunomodulatory agents, including avadomide.
114 of systemic and topical anti-inflammatory or immunomodulatory agents, including prednisolone acetate,
115  has prompted investigation of more targeted immunomodulatory agents, including thalidomide.
116 s are augmented by the administration of the immunomodulatory agent interleukin (IL)-2.
117 her conditions before starting most systemic immunomodulatory agents is recommended in patients with
118                             Lenalidomide, an immunomodulatory agent, is effective as monotherapy for
119  for minocycline as an anti-inflammatory and immunomodulatory agent, its utility in the treatment of
120 t with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide)
121                   These results suggest that immunomodulatory agents may provide a treatment option f
122 ients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors.
123 apy, including a proteasome inhibitor and an immunomodulatory agent, or were refractory to both drug
124                       Here, we show that the immunomodulatory agent pomalidomide depletes pancreatic
125 igand 1 (PD-L1) inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell
126                                              Immunomodulatory agents potentially represent a new clas
127  purine metabolic pathway (e.g. forodesine), immunomodulatory agents, proapoptotic small molecules (e
128                          The introduction of immunomodulatory agents, proteasome inhibitors, and auto
129 d two to four regimens previously (including immunomodulatory agents, proteasome inhibitors, and dara
130                 Transient treatment with the immunomodulatory agent rapamycin (sirolimus) allows for
131                                              Immunomodulatory agents recently examined in patients wi
132          Conversely, when locally delivered, immunomodulatory agents require repeated administration
133 L is increasing with the introduction of new immunomodulatory agents, several of which target T cells
134      In combination with currently available immunomodulatory agents, SFK inhibition could potentiall
135                                     Numerous immunomodulatory agents showing promise in preclinical s
136 eptides to autoreactive T cells or to direct immunomodulatory agents such as interleukins or cytolyti
137  be used either alone or in combination with immunomodulatory agents such as topical steroids.
138  complex mechanisms of action of pleiotropic immunomodulatory agents, such as glucocorticoids, vitami
139                                    Recently, immunomodulatory agents, such as immune checkpoint inhib
140                                        Novel immunomodulatory agents, such as infliximab, have shown
141                                              Immunomodulatory agents, such as steroids, plasmapheresi
142                     New active drugs include immunomodulatory agents, such as thalidomide and CC-5013
143 vir-ritonavir, inhibit viral replication and immunomodulatory agents, such as tocilizumab and baricit
144 ht thus be expanded with its use as a potent immunomodulatory agent targeting Treg in cancer immunoth
145  as mycophenolate mofetil and a new class of immunomodulatory agents targeting cytokines, in particul
146 servations suggest that bergenin is a potent immunomodulatory agent that could be further explored as
147                             Lenalidomide, an immunomodulatory agent that enhances antibody-dependent
148 ren, NJ) is a putative anti-angiogenesis and immunomodulatory agent that has demonstrated activity in
149                     Atorvastatin is a potent immunomodulatory agent that holds promise as a novel and
150       We conclude that B. subtilis EPS is an immunomodulatory agent that induces hybrid macrophages t
151                            FTY720 is a novel immunomodulatory agent that inhibits lymphocyte traffick
152                            Bz-423 is a novel immunomodulatory agent that is active against disease ev
153 ug against tumor cells, but also as a potent immunomodulatory agent that selectively impairs MDSC-ind
154 the treatment of immune-mediated diseases by immunomodulatory agents that alter the cytokine milieu i
155   Thus, efforts must be made to identify new immunomodulatory agents that are effective through a nov
156                               Development of immunomodulatory agents that enhance innate immune respo
157                         They can also act as immunomodulatory agents that favor a Th2 polarization.
158 tic and antibiotic sparing roles for vaginal immunomodulatory agents that specifically target HDP ind
159 plore the GSK-3beta inhibitor 9-ING-41 as an immunomodulatory agent to increase tumor immune recognit
160 al uses general (rather than tumor-specific) immunomodulatory agents to boost the number and activity
161 1D progression and monitoring the ability of immunomodulatory agents to clear insulitis.
162 e a mechanistic rationale for using PARPi as immunomodulatory agents to harness the therapeutic effic
163 2, MERS, and FIP is focused on antiviral and immunomodulatory agents to inhibit virus replication and
164 ely aging population, advances in the use of immunomodulatory agents to treat a rising number of dise
165                      Thalidomide (THD) is an immunomodulatory agent used to treat immune-mediated dis
166           Pegylated interferon alfa-2a is an immunomodulatory agent used to treat polycythemia vera.
167     Glucocorticoids continue to be the major immunomodulatory agents used in clinical medicine today.
168  The absence of the use of a steroid-sparing immunomodulatory agent was the strongest predictive fact
169                        Systemic steroids and immunomodulatory agents were successfully used to contro
170 ed only moderate efficacy for any particular immunomodulatory agent, whereas new data have confirmed
171 for IPF are limited to anti-inflammatory and immunomodulatory agents, which are only partially effect
172 primarily based on corticosteroids and other immunomodulatory agents, which should be prescribed care
173  pathways and into the biological effects of immunomodulatory agents will help to optimize or adopt t
174  the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties,
175                      Lenalidomide is a novel immunomodulatory agent with antiproliferative activities
176                           Lenalidomide is an immunomodulatory agent with biological activity in sever
177                           Lenalidomide is an immunomodulatory agent with proven tumoricidal and antip
178                           Lenalidomide is an immunomodulatory agent with therapeutic activity in chro
179                           Lenalidomide is an immunomodulatory agent with wide-ranging properties.

 
Page Top